Takeda Pharmaceutical Co Ltd - Oct 26, 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
10%+ Owner
Signature
/s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited
Stock symbol
XLO
Transactions as of
Oct 26, 2021
Transactions value $
$0
Form type
4
Date filed
10/26/2021, 08:31 PM
Previous filing
Oct 21, 2021
Next filing
Nov 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLO Common Stock Conversion of derivative security +1.48M 1.48M Oct 26, 2021 See explanation F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Series B Preferred Stock Conversion of derivative security $0 -1.25M -100% $0.00* 0 Oct 26, 2021 Common Stock 1.25M See explanation F1, F2, F3
transaction XLO Series C Preferred Stock Conversion of derivative security $0 -227K -100% $0.00* 0 Oct 26, 2021 Common Stock 227K See explanation F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Takeda Pharmaceutical Co Ltd is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuers Common Stock on a one-for-one basis immediately prior to the completion of the Issuers initial public offering for no additional consideration. The Preferred Stock had no expiration date.
F2 This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc.
F3 The reportable securities are owned directly by Takeda Ventures, Inc. Takeda Pharmaceutical Company Limiteds beneficial ownership of these securities is comprised of the reportable securities owned by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.